roginolisib   Click here for help

GtoPdb Ligand ID: 12487

Synonyms: compound 1 [WO2022207646A1] | compound 339 [US9073940] [1] | IOA244 | MSC-2360844 | MSC2360844
Compound class: Synthetic organic
Comment: A name-to-structure disclosure was made in Spring 2023 [2], which confirmed our speculation that compound 1 that we had previously identified from WO2022207646A1 is iOnctura's semi-allosteric, PI3Kδ-selective inhibitor IOA-244 [3]; indeed the structure in WO2022207646 mapped to the synonym IOA-244 in PubChem CID 66580799, and the code is used in the patent (although it's not explicitly associated to compound 1). The same chemical structure was claimed in a 2015 Merck patent [1]. Publication of proposed INN list 129 (August 2023) confirmed our expectation that IOA-244 is "roginolisib".
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 100.13
Molecular weight 526.58
XLogP -0.71
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES C1=CC2=C(C(=C1)F)S(=O)(=O)CC3=C2N(C4=CC=C(C=C4)CN5CCOCC5)N=C3C(=O)N6CCOCC6
InChI InChI=1S/C26H27FN4O5S/c27-22-3-1-2-20-24-21(17-37(33,34)25(20)22)23(26(32)30-10-14-36-15-11-30)28-31(24)19-6-4-18(5-7-19)16-29-8-12-35-13-9-29/h1-7H,8-17H2
1. Gaillard P, Jeanclaude-Etter I, Pomel V, Sebille E, Jeyaprakashnarayanan S, Muzerelle M. (2015)
Tricyclic pyrazol amine derivatives.
Patent number: US9073940B2. Assignee: Merck Serono SA. Priority date: 12/11/2010. Publication date: 07/07/2015.
2. Johnson Z, Tarantelli C, Civanelli E, Cascione L, Spriano F, Fraser A, Shah P, Nomanbhoy T, Napoli S, Rinaldi A et al.. (2023)
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Cancer Res Commun, 3 (4): 576-591. [PMID:37066023]
3. Pickering C, Van Der Veen L, Lahn M, Zorrilla R, Johnson Z. (2022)
A pi3k-delta inhibitor for use in treatment regimens.
Patent number: WO2022207646A1. Assignee: Ionctura Sa. Priority date: 29/03/2021. Publication date: 06/10/2022.